Xerostomia from Radiotherapy

What is Xerostomia from Radiotherapy?

Xerostomia means “dry mouth.” When it occurs as a result of radiotherapy, the condition is caused by damage to the salivary glands that receive radiation doses for head‑and‑neck cancers, nasopharyngeal tumors, or certain brain malignancies. Saliva is essential for chewing, swallowing, speaking, protecting teeth, and defending the mouth against infection. Radiation‑induced xerostomia can be temporary or, more often, permanent, depending on the total dose, fractionation schedule, and the specific glands exposed.

According to the Mayo Clinic, patients may notice a “sticky” feeling, difficulty forming a coherent speech, or an increased need to sip water. The severity ranges from mild discomfort to a debilitating condition that impacts nutrition, oral health, and quality of life.

Common Causes

While radiotherapy is a primary trigger for xerostomia in cancer patients, several other conditions can produce similar dry‑mouth symptoms. Understanding the broader landscape helps patients and clinicians differentiate the underlying mechanisms.

• Head‑and‑neck radiation therapy (≥ 30 Gy to parotid or submandibular glands)
• Medications – antihistamines, antidepressants, anticholinergics, diuretics, and certain antihypertensives
• Sjögren’s syndrome – an autoimmune disorder targeting exocrine glands
• Diabetes mellitus – chronic hyperglycemia can impair glandular function
• Dehydration – from fever, vomiting, or inadequate fluid intake
• Neurological diseases – Parkinson’s, multiple sclerosis, or stroke affecting autonomic nerves
• Age‑related changes – salivary flow naturally declines after age 65
• Tobacco and alcohol use – both have a drying effect on oral tissues
• Systemic chemotherapy – especially when combined with radiation (chemoradiation)
• Radiation to the brain or spinal cord – can indirectly affect the hypothalamic‑pituitary axis and saliva production

Associated Symptoms

Dry mouth rarely occurs in isolation. The following signs often accompany radiation‑induced xerostomia:

• Difficulty chewing, swallowing (dysphagia), or tasting food
• Increased dental decay and oral mucosal infections (candidiasis)
• Burning or tingling sensation on the tongue, lips, or palate
• Hoarseness or change in voice quality
• Bad breath (halitosis) due to reduced natural cleansing
• Cracked, sore, or ulcerated corners of the mouth (angular cheilitis)
• Thick, stringy saliva that may appear suddenly when stimulated
• Dry, gritty feeling in the throat, especially at night

When to See a Doctor

Because xerostomia can quickly lead to secondary problems, timely medical attention is essential. Seek professional care if you notice any of the following:

• Persistent dry mouth lasting more than 2 weeks after completing radiotherapy
• Unexplained weight loss or difficulty swallowing solid foods
• Frequent mouth sores, thrush, or persistent sore throat
• New or worsening tooth pain, cavities, or gum bleeding
• Changes in taste that affect nutrition
• Persistent hoarseness or voice changes lasting >4 weeks
• Any symptom that interferes with sleep, work, or social activities

Early evaluation can prevent complications such as severe dental decay, malnutrition, or aspiration pneumonia.

Diagnosis

Doctors use a combination of history, physical examination, and objective tests to confirm xerostomia and gauge its severity.

Clinical Evaluation

• Medical history – details of radiation dose, fields treated, medications, and comorbidities.
• Oral examination – assessment of mucosal integrity, saliva pooling, dental status, and signs of infection.

Objective Tests

• Salivary flow measurement – sialometry (unstimulated flow < 0.1 mL/min is considered severe) and stimulated flow after citric acid or chewing gum.
• Salivary scintigraphy – nuclear medicine scan evaluates glandular uptake and excretion.
• Ultrasound or MRI – may be used to assess gland size and fibrosis after high‑dose radiation.
• Microbiological swabs – to detect candidiasis or bacterial overgrowth when infection is suspected.

Reference: National Cancer Institute, “Management of Radiation‑Induced Xerostomia,” NIH, 2022.

Treatment Options

Management is multimodal, combining medical therapy, oral hygiene strategies, and lifestyle modifications.

Medical Interventions

• Saliva substitutes – over‑the‑counter sprays, gels, or lozenges (e.g., Biotène, Saliva‑max). Choose sugar‑free products to limit caries.
• Systemic sialagogues –
  • Pilocarpine 5 mg PO three times daily (FDA‑approved for xerostomia)
  • Cevimeline 30 mg PO twice daily (effective for Sjögren’s, useful off‑label for radiation cases)
  These stimulate muscarinic receptors on salivary glands. Contraindications include uncontrolled asthma, glaucoma, or cardiac arrhythmias.
• Topical muscarinic agonists – experimental lozenges containing low‑dose pilocarpine are being studied (clinicaltrials.gov NCT04891762).
• Antifungal therapy – for confirmed candidiasis (e.g., nystatin oral suspension 100,000 U mL⁻¹ q.i.d. or fluconazole 100 mg PO daily).
• Low‑level laser therapy (LLLT) – several RCTs have shown improved salivary output when applied to parotid tissue post‑radiation (Cleveland Clinic, 2021).

Home & Lifestyle Measures

• Sip water or sugar‑free electrolyte drinks frequently (every 15–30 min).
• Chew sugar‑free gum or suck on xylitol lozenges to stimulate residual salivary function.
• Maintain meticulous oral hygiene: brush twice daily with fluoride toothpaste, floss, and use an alcohol‑free antimicrobial mouth rinse (e.g., 0.12% chlorhexidine) for short periods.
• Avoid alcohol, caffeine, and tobacco, which exacerbate dryness.
• Use a humidifier at night to keep airway mucosa moist.
• Consume soft, moist foods (soups, stews, smoothies) and avoid overly salty, spicy, or acidic items that irritate a dry mouth.
• Apply a thin layer of petroleum‑based ointment (e.g., Vaseline) on the lips before bedtime.

All interventions should be discussed with a radiation oncologist or oral medicine specialist to tailor therapy to the individual’s radiation dose and overall health.

Prevention Tips

Although xerostomia is often an unavoidable side‑effect of curative head‑and‑neck radiation, proactive steps can reduce severity:

• Intensity‑Modulated Radiation Therapy (IMRT) – precisely shapes the radiation dose, sparing at least one parotid gland to a mean dose < 26 Gy, which markedly lowers xerostomia risk (American Society for Radiation Oncology, 2020).
• Parotid‑sparing techniques – use of customized mouthpieces or tongue‑depressors to displace glands.
• Amifostine – a radioprotective cytoprotective agent given intravenously before each radiation session; shown to reduce xerostomia incidence in randomized trials (Mouth Cancer Research, 2019).
• Pre‑treatment dental evaluation and prophylactic fluoride trays to minimize post‑radiation caries.
• Baseline hydration and nutritional counseling before therapy begins.
• Early initiation of saliva‑stimulating agents (pilocarpine) during the radiation course, when tolerated.
• Regular follow‑up with an oral health professional during and after treatment to catch early changes.

Emergency Warning Signs

Key Take‑aways

Radiotherapy‑induced xerostomia is a common, often chronic side‑effect that impacts oral health, nutrition, and quality of life. Prompt recognition, thorough diagnostic work‑up, and a combination of pharmacologic and self‑care strategies can alleviate symptoms and prevent serious complications. Patients undergoing head‑and‑neck radiation should receive preventive counseling, regular dental assessments, and close follow‑up with their oncology and oral health teams.

---

References:

1. Mayo Clinic. Dry Mouth (Xerostomia). 2023. https://www.mayoclinic.org
2. National Cancer Institute. Management of Radiation‑Induced Xerostomia. NIH, 2022.
3. American Society for Radiation Oncology. Guidelines for Parotid‑Sparing IMRT. 2020.
4. Cleveland Clinic. Low‑Level Laser Therapy for Radiation‑Induced Xerostomia. 2021.
5. World Health Organization. Oral Health Fact Sheet. 2022.
6. ClinicalTrials.gov. Pilocarpine Lozenge for Post‑Radiation Xerostomia. NCT04891762.
7. Journal of Oral Oncology. Amifostine reduces xerostomia incidence. 2019.